Safe and Effective Drug for Hepatitis C Genotype 4
FDA approves Technivie for treatment of chronic hepatitis C genotype 4
The U.S. Food and Drug Administration today approved Technivie (ombitasvir, paritaprevir and ritonavir) for use in combination with ribavirin for the treatment of hepatitis C virus (HCV) genotype 4 infections in patients without scarring and poor liver function (cirrhosis).
Technivie in combination with ribavirin is the first drug that has demonstrated safety and efficacy to treat genotype 4 HCV infections without the need for co-administration of interferon, an FDA-approved drug also used to treat HCV infection.
Continue reading this FDA News Release:
New Hepatitis C Treatment Approved By the FDA
FDA Grants Priority Review: Once-Daily, Single-Tablet Combination for HCV